13.01
0.32 (2.52%)
| Previous Close | 12.69 |
| Open | 12.57 |
| Volume | 532,404 |
| Avg. Volume (3M) | 660,067 |
| Market Cap | 905,195,456 |
| Price / Sales | 12.94 |
| Price / Book | 2.67 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Profit Margin | -160.80% |
| Operating Margin (TTM) | -71.60% |
| Diluted EPS (TTM) | -1.62 |
| Quarterly Revenue Growth (YOY) | 83.30% |
| Total Debt/Equity (MRQ) | 5.47% |
| Current Ratio (MRQ) | 3.40 |
| Operating Cash Flow (TTM) | -110.04 M |
| Levered Free Cash Flow (TTM) | -52.16 M |
| Return on Assets (TTM) | -14.57% |
| Return on Equity (TTM) | -30.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Zymeworks Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 1.30 |
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 102.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ecor1 Capital, Llc | 31 Dec 2024 | 15,028,079 |
| Rubric Capital Management Lp | 31 Dec 2024 | 3,917,331 |
| Bnp Paribas Asset Management Holding S.A. | 31 Dec 2024 | 2,137,653 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame | 31 Dec 2024 | 1,365,111 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (LifeSci Capital, 130.59%) | Buy |
| Median | 19.00 (46.04%) | |
| Low | 13.00 (HC Wainwright & Co., -0.08%) | Hold |
| Average | 20.67 (58.88%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 11.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| LifeSci Capital | 11 Mar 2025 | 30.00 (130.59%) | Buy | 11.70 |
| HC Wainwright & Co. | 10 Mar 2025 | 13.00 (-0.08%) | Hold | 11.10 |
| Citigroup | 07 Mar 2025 | 19.00 (46.04%) | Buy | 12.00 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |